Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2005
11/17/2005US20050255549 IRAK-4: compositions and methods of use
11/17/2005US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/17/2005US20050255518 Methods and compositions for the treatment and diagnosis of pain disorders using 46566
11/17/2005US20050255443 Method of screening cell growth inhibitor and cell growth inhibitor
11/17/2005US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
11/17/2005US20050255151 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
11/17/2005US20050255126 biologically pure strain of Aureobasidium pullulans isolated from a food source; culturing in a medium containing saccharides as a carbon source; has resistance to the antibiotic cycloheximide
11/17/2005DE10392697T5 Herstellung und Standardisierung von immunmodulierenden Peptid-verknüpften Glucanen mit nachweisbarer oraler Resorbierbarkeit aus Coriolus Versicolor Preparation and standardization of immunomodulating peptide-linked glucans with detectable oral absorbability from Coriolus Versicolor
11/17/2005CA2566184A1 Imidazopyridine compound
11/17/2005CA2566083A1 Antifatigue composition
11/17/2005CA2565250A1 Cysteamines for treating complications of hypercholesterolemia and diabetes
11/16/2005EP1595951A1 Diagnosis and treatment of diseases using peptides which are bound by specific anti-anti-t-cell receptor vbeta antibodies
11/16/2005EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
11/16/2005EP1595869A1 Pyrimidine derivatives
11/16/2005EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
11/16/2005EP1595866A1 Compound inhibiting dipeptidyl peptidase iv
11/16/2005EP1595549A1 Dispersant for sustained release preparations
11/16/2005EP1595545A1 Blood-vessel-growth promoter
11/16/2005EP1595544A1 Remedy for diabetes
11/16/2005EP1595543A2 Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil
11/16/2005EP1595539A1 Drug for reducing side effects in ribavirin interferon combination therapy
11/16/2005EP1492795B1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
11/16/2005EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha
11/16/2005EP1476429B1 Novel pyridine- and quinoline-derivatives
11/16/2005EP1463823A4 Methods of increasing endogenous erythropoietin (epo)
11/16/2005EP1450782B1 Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction
11/16/2005EP1409488B1 Imidazo-triazine derivatives as ligands for gaba receptors
11/16/2005EP1397129B1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/16/2005EP1379516B1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists
11/16/2005EP1370557B1 Benzimidazole anti-inflammatory compounds
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1363623B1 Peptide deformylase inhibitors
11/16/2005EP1357955B1 Drug delivery from stents
11/16/2005EP1347982B1 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
11/16/2005EP1317442B1 Quinolinone derivatives as tyrosine kinase inhibitors
11/16/2005EP1289517B1 Pharmaceutical compositions comprising cannabidiol derivatives
11/16/2005EP1257550B1 Platelet adp receptor inhibitors
11/16/2005EP1239824B1 Scar treatment composition comprising a silicone mixture
11/16/2005EP1237543B1 Effervescent histamine h2 antagonist composition
11/16/2005EP1222191B1 Benzodiazepin derivatives, the production and use thereof
11/16/2005EP1222182B1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
11/16/2005EP1220661B1 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid
11/16/2005EP1218374B1 Pharmaceutically active sulfonamide derivatives
11/16/2005EP1213353B1 Peptide leukotriene receptor
11/16/2005EP1212097B1 Enzyme inhibitors
11/16/2005EP1207886B1 Sphingomyelinase inhibitors as agents with antiapoptotic and antiseptic action
11/16/2005EP1114052B1 4-aminopyrrolopyrimidines as kinase inhibitors
11/16/2005EP1011635B1 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
11/16/2005EP0981517B1 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides
11/16/2005EP0977738B1 Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer
11/16/2005EP0876395B1 Inhibitors of interleukin-1beta converting enzyme
11/16/2005EP0873406B1 Protein induced by deprenyl
11/16/2005CN1697878A Novel peptides having cAMP producing activity
11/16/2005CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists
11/16/2005CN1697830A 嘧啶衍生物 Pyrimidine derivatives
11/16/2005CN1697655A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/16/2005CN1697653A Particulate product comprising pantethine
11/16/2005CN1227359C Down-regualtion resistant C3 convertase
11/16/2005CN1227251C Carbamates derived from arylalkylamines
11/16/2005CN1227249C Pyrimidine compounds
11/16/2005CN1227248C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
11/16/2005CN1227241C Arylpiperazines having activity at the serotnin 1A receptor
11/16/2005CN1227237C Piperazinylpyrazines compounds as antagonists of serotonin-5-HT2 receptor
11/16/2005CN1227233C 5-chloro-3-(4-methane sulfonylphenyl)-6-methyl-[2,3'] bipyridine and process for synthesis
11/16/2005CN1227232C Process for preparing non-steroid glucocorticoid receptor regulator
11/16/2005CN1227230C Prodrugs to NMDA receptor lagans
11/16/2005CN1227035C Conjugates and method for production thereof, and their use for transporting molecules via biological membranes
11/16/2005CN1227033C Method of treating cancer with anti-neurotrophin agents
11/16/2005CN1227030C Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
11/16/2005CN1227029C Combination of hypertension converting enzyme inhibitor with a diuretic for treating microcirculation disorders
11/16/2005CN1227025C Improved methods for processing activated protein C
11/16/2005CN1227018C Chinese medicine for health of driver
11/16/2005CN1227012C Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
11/16/2005CN1227011C Method of treating adenosine depletion
11/16/2005CN1227008C Method of converting COX-2 inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
11/16/2005CN1227007C Cannabinoid drugs
11/16/2005CN1227006C Pharmaceuticals comprising N,N'-BIS(2-Hydroxybenzy) ethylenediamine-N, N'-diacetic acid for iron chelating therapy
11/16/2005CN1227004C Partial fatty acid oxidation inhibitors in treatment of congestive heart failure
11/16/2005CN1226999C Solubilized pharmaceutical composition for parenteral administration
11/15/2005US6965039 7-carboxy-flavone derivatives preparation method and therapeutic use
11/15/2005US6965033 Bisamidate phosphonate prodrugs
11/15/2005US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
11/15/2005US6965018 Antibodies directed to B7-related polypeptide, BSL-2
11/15/2005US6964983 Compounds that modulate PPAR activity and methods for their preparation
11/15/2005US6964978 Dissolving with crystal growth inihibitos; drying
11/15/2005US6964977 E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer
11/15/2005US6964975 Isoxazole and thiazole compounds and use thereof as medicine
11/15/2005US6964974 2,3-oxidosqualene-lanosterol cyclase inhibitors
11/15/2005US6964973 Nonsteroidal agonists and antagonists
11/15/2005US6964972 8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
11/15/2005US6964971 Oral administering; sustained release
11/15/2005US6964970 Heterocyclic amines such as 2-benzoyl-1,3,4,9-tetrahydro-2H-pyrido(3,4-b)indole, used preferential inhibitors of fatty acid biosynthesis in bacterial systems; bactericides
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964965 Corticotropin releasing factor antagonists
11/15/2005US6964960 Indoloquinazolinones
11/15/2005US6964959 Use of a methylol-containing compound to treat tumors
11/15/2005US6964957 For use in therapy of neurodegenerative diseases and certain cancers
11/15/2005US6964956 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization
11/15/2005US6964955 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
11/15/2005US6964953 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
1 ... 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 ... 1564